Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic
July 28, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic - JCN Newswire
Share:
Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic

Osaka, Dec 13, 2006 - (JCN Newswire) - Dainippon Sumitomo Pharma Co., Ltd. ('DSP') has today announced it has decided to succeed the overseas clinical development of Lurasidone (SM-13496), which was discovered by DSP and under clinical development for the treatment of schizophrenia, from Merck & Co.,Inc. Furthermore, DSP has already started its review of the clinical development program to be continued by DSP in the US and Europe.

The compound was licensed to Merck in June 2005 for exclusive global development rights except Japan, China, Taiwan and Korea and was under development. Merck has decided discontinuation of the development of Lurasidone and returns its rights to DSP. DSP has been considering continuation of the development with cooperation of its overseas subsidiaries.

Lurasidone is in Phase IIb development by DSP in Japan for the treatment of schizophrenia.

About Dainippon Sumitomo

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals merged on October 1, 2005, to create Dainippon Sumitomo Pharma (TSE: 4506), a new corporation committed to serving the social good through research and development programs designed to empower people to lead fuller, healthier lives. Among the capabilities being deployed to create new value for shareholders and customers alike are research and development programs that excel in sophistication and creativity, quality and production systems that ensure the enduring trust of our customers, some of Japan's most developed sales and marketing resources, and an unmatched ability to provide reliable data to medical decision-makers. For more information, please visit www.ds-pharma.co.jp

Contact:

Dainippon Sumitomo Pharma Co., Ltd.
Public Relations Department
Tel: +81-6-6203-1407
Fax: +81-6-6203-5548
 


Dec 13, 2006
Source: Dainippon Sumitomo

Dainippon Sumitomo (TSE: 4506) (U.S: DNPUF)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Licensing Agreement
View more news from these Sectors: Drugs & OTC, Drugs & OTC


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)